Back
HBV Disease Progression 
Liver Cancer/HCC
Liver Cancer/HCC
Liver Cancer/HCC
Two Studies Look at Promising Therapies for Liver Cancer: Sorafenib and Doxorubicin
- Details
- Category: Liver Cancer/HCC
- Published on Friday, 25 July 2008 00:00
- Written by Liz Highleyman
Two recently published studies produced promising data on experimental therapies for HCC: the systemic chemotherapy drug sorafenib (Nexavar), and combination therapy using doxorubicin-eluting beads plus radiofrequency ablation.
EASL 2008: Sorafenib (Nexavar) Improves Outcomes in Patients with Hepatocellular Carcinoma
- Details
- Category: Liver Cancer/HCC
- Published on Friday, 16 May 2008 00:00
- Written by Liz Highleyman
In a late-breaker presentations at the 43rd annual meeting of the European Association for the Study of the Liver (EASL 2008) last month in Milan, researchers discussed data from the SHARP study, which evaluated sorafenib (Nexavar) as a therapy for HCC. Sorafenib, which was already approved for primary kidney cancer, recently received U.S. Food and Drug Administration (FDA) approval for unresectable (not curable by surgery) HCC.
Web Design and Development by